Resonance Health Limited

RHT AU

RHT AUResonance Health Limited

Australia Composite

0.06

AUD

- -

28.12MMarket Cap

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Resonance Health Limited

RHT:AU

(Australia Composite)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

Legends:

Stock price

Beta (1.0 Market)

% total return 06/15

Stock

S&P500

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
- -	0.01	0.01	- -	- -	- -	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	Revenue per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Basic EPS, GAAP
- -	- -	9.2	- -	- -	- -	- -	6.62	- -	- -	- -	- -	- -	- -	- -	- -	- -	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.02	Book Value per Share
0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	- -	- -	0.01	0.02	0.02	0.02	0.02	0.02	Tangible Book Value per Share
363	364	364	365	365	365	364	398	398	402	402	406	432	450	461	461	445	Basic Weighted Avg Shares
2	2	2	2	2	2	2	2	3	2	3	4	4	4	4	4	4	Sales/Revenue/Turnover
-22.25	19.32	-20.91	-31.2	-46.04	-45.82	3.2	-4.62	-19.38	-25.03	-9	23.92	-32.17	4.98	-46.3	-36.89	-42.08	Operating Margin (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Depreciation Expense
- -	1	- -	- -	- -	- -	- -	- -	- -	- -	- -	1	-1	1	-1	-1	-1	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Effective Tax Rate (%)
-2.4	27.31	-5.57	-18.15	-17.19	-11.31	-3.17	18.96	-15.09	-12.24	7.76	35.05	-19.49	15.5	-29.83	-17.72	-34.01	Profit Margin (%)
3	3	3	2	1	1	2	3	2	1	2	3	7	9	8	7	7	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	LT Debt
3	3	3	3	3	2	3	4	4	4	4	6	10	12	11	10	10	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Capital (%)
-1.58	21.24	-3.23	-10.66	-10	-7.01	-2.49	11.5	-8.69	-7.44	5.54	25.8	-10.56	6.65	-12.42	-9.48	-16.42	Return on Common Equity (%)

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	12.06%	9.14%	15.06%
Net Income, GAAP	-137.47%	-39.85%	-31.65%
Free Cash Flow	-238.49%	-269%	-71.06%
Total Cash Common Dividend	- -	- -	- -
Total Equity	18.71%	22.67%	-7.07%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Business: Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also provides quantitative imaging measurements and CRO services, such as quality-assured image analysis, project and data management, and issue resolution services; biomarkers, genomics, and laboratory analysis services, as well as works with third party pathology laboratories for blood/sample collection and for standard biochemical/lab safety assessments; design and protocol development, and project management and monitoring services; assessment of subject inclusion or exclusion, evaluating the safety profile of a new therapy, and supporting primary and secondary end-points demonstrating drug efficacy services; and phantoms for the MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.

	Jun'21	Jun'22	Jun'23
ST Debt	- -	- -	- -
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	461	461	461
Market Capitalization	78	28	18

2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	TTM
- -	0.01	0.01	- -	- -	- -	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	Revenue per Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Basic EPS, GAAP
- -	- -	9.2	- -	- -	- -	- -	6.62	- -	- -	- -	- -	- -	- -	- -	- -	- -	Free Cash Flow per Basic Share
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Dividend per Share
0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.02	Book Value per Share
0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	- -	- -	0.01	0.02	0.02	0.02	0.02	0.02	Tangible Book Value per Share
363	364	364	365	365	365	364	398	398	402	402	406	432	450	461	461	445	Basic Weighted Avg Shares
2	2	2	2	2	2	2	2	3	2	3	4	4	4	4	4	4	Sales/Revenue/Turnover
-22.25	19.32	-20.91	-31.2	-46.04	-45.82	3.2	-4.62	-19.38	-25.03	-9	23.92	-32.17	4.98	-46.3	-36.89	-42.08	Operating Margin (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Depreciation Expense
- -	1	- -	- -	- -	- -	- -	- -	- -	- -	- -	1	-1	1	-1	-1	-1	Net Income, GAAP
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Effective Tax Rate (%)
-2.4	27.31	-5.57	-18.15	-17.19	-11.31	-3.17	18.96	-15.09	-12.24	7.76	35.05	-19.49	15.5	-29.83	-17.72	-34.01	Profit Margin (%)
3	3	3	2	1	1	2	3	2	1	2	3	7	9	8	7	7	Working Capital
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	LT Debt
3	3	3	3	3	2	3	4	4	4	4	6	10	12	11	10	10	Total Equity
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Invested Capital (%)
- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	Return on Capital (%)
-1.58	21.24	-3.23	-10.66	-10	-7.01	-2.49	11.5	-8.69	-7.44	5.54	25.8	-10.56	6.65	-12.42	-9.48	-16.42	Return on Common Equity (%)

	Jun'21	Jun'22	Jun'23
Total Current Assets	10	8	8
Accounts Receivable, Net	1	1	1
Cash, Cash Equivalents & STI	9	7	6
Inventories	- -	- -	- -
Total Current Liabilities	1	1	1
Payables & Accruals	- -	1	1
ST Debt	- -	- -	- -
Deferred Revenue	- -	- -	- -